Next 10 |
Sigyn Therapeutics (OTCQB: SIGY) , a development-stage medical technology company, today announced financial results for the first quarter ended March 31, 2024. During the quarter, the company reported a loss from operations of $629,972, as compared to an operating loss of $521,258 for the compar...
SAN DIEGO, CA - ( NewMediaWire ) - May 15, 2024 - Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced financial results for the first quarter ended March 31, 2024. During the quarter, the C...
Sigyn Therapeutics (OTCQB: SIGY) , a development-stage medical technology company, today announced that it has published an article entitled: “Sigyn Therapy(TM), an Emerging Candidate to Address Endotoxemia, Sepsis and Drug-Resistant Viral & Bacterial Infections.” “Wh...
SAN DIEGO, CA - ( NewMediaWire ) - May 07, 2024 - Sigyn Therapeutics, Inc. (“Sigyn Therapeutics”, “Sigyn” or the “Company”) (OTCQB: “SIGY”), a development-stage medical technology company, announced today that it has published an article ent...
Sigyn Therapeutics (OTCQB: SIGY) , a medical technology that creates medical solutions to treat life-threatening conditions, is developing a portfolio of technologies, including Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM) and ImmunePrep(TM), which have each been designed to overcome a current...
Sigyn Therapeutics (OTCQB: SIGY) , a medical technology company, is developing blood purification technologies to treat life-threatening conditions that are not addressed with current market-cleared drug agents as well as an expansive pipeline of technologies to optimize the benefit of cancer the...
Sigyn Therapeutics (OTCQB: SIGY) , a development-stage medical technology company, recently expanded its therapeutic candidates, introducing ImmunePrep(TM) to improve the delivery of immunotherapeutic antibodies to treat cancer. “The company is also developing ChemoPrep(TM) and ChemoP...
Sigyn Therapeutics (OTCQB: SIGY) , a development-stage medical technology company, is currently focused on the development of four therapeutic candidates to address clearly defined limitations in global health. These include the ImmunePrep(TM) platform to enhance the performance of immunotherapeu...
Sigyn Therapeutics is developing four medical device candidates – Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM) – designed to overcome current therapeutic limitations in healthcare Sigyn Therapy(TM), the company’s lead product candidate, is a single-us...
Sigyn’s common stock, temporarily trading under the ticker symbol “SIGYD”, is set to revert back to its historic symbol “SIGY” on February 29, 2024. The company, as part of its 2023 Year-End Report, summarized its development of medical technologies that targe...
News, Short Squeeze, Breakout and More Instantly...
Sigyn Therapeutics Inc Company Name:
SIGY Stock Symbol:
OTCMKTS Market:
Sigyn Therapeutics Inc Website:
Sigyn Therapeutics (OTCQB: SIGY) , a development-stage medical technology company, today announced financial results for the first quarter ended March 31, 2024. During the quarter, the company reported a loss from operations of $629,972, as compared to an operating loss of $521,258 for the compar...
SAN DIEGO, CA - ( NewMediaWire ) - May 15, 2024 - Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced financial results for the first quarter ended March 31, 2024. During the quarter, the C...
Sigyn Therapeutics (OTCQB: SIGY) , a development-stage medical technology company, today announced that it has published an article entitled: “Sigyn Therapy(TM), an Emerging Candidate to Address Endotoxemia, Sepsis and Drug-Resistant Viral & Bacterial Infections.” “Wh...